Sinopharm Refutes Claim Of Increasing Stake In Sinopharm Medicine Holding
This article was originally published in PharmAsia News
In response to a China Times article that said Sinopharm plans to increase its stake in Sinopharm Medicine Holding by 30 percent, which would delay the latter's listing in Hong Kong, Sinopharm has issued a statement refuting the claim. It denied seeking approval from relevant authorities for the move. Fosun Pharma, the second largest shareholder of Sinopharm Medicine Holding, also released an announcement rejecting the report published on March 18. (Click here for more - Chinese Language)
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?